美诺华(603538.SH)：全资子公司获得非布司他片药品注册证书

Core Viewpoint - Menova (603538.SH) has received approval from the National Medical Products Administration for its subsidiary, Ningbo Menova Tiankang Pharmaceutical Co., Ltd., to produce and sell Febuxostat tablets, which are indicated for the long-term treatment of hyperuricemia in gout patients [1] Group 1 - The approval of Febuxostat tablets marks the company's qualification for production and sales in the domestic market [1] - This development enhances the company's product competitiveness in the market [1] - The addition of this drug enriches the company's formulation product pipeline [1] - The approval is expected to have a positive impact on the company's operational development [1]